$STEK Stemtech Corporation and Seacret Direct / Vi
Post# of 106825
(Total Views: 128)
Posted On: 01/15/2025 12:05:18 PM
$STEK Stemtech Corporation and Seacret Direct / Viago Execute Merger Agreement
Stemtech Corporation (OTC-BB:STEK) is pleased to announce the merger agreement with Seacret Direct / VIÁGO, progressing their plan to establish a global leadership position in defining the future of lifestyle, health and longevity. The transaction will be completed through the issuance of 13 million preferred shares with a stated value of $2.50 per share.
Stemtech Corporation ("Company"
and Seacret have signed the agreement to complete the previously announced merger. The completion of this transaction remains subject conditions, including the audit of Seacret Direct / VIÁGO, consents and authorizations of the preferred stock and other customary conditions.
This transaction marks a pivotal milestone in the Company's evolution, expected to double the Stemtech revenue, in combination. The merger creates a vertically integrated powerhouse poised to lead and redefine health, longevity, and lifestyle for a public that demands smarter, more comprehensive solutions to improving quality of daily life. Highlighting a consolidated revenue forecast of double or more for 2025 with planned cost synergies, the merger is set to deliver positive bottom-line results through optimization and existing growth trajectories alone.
The Company will focus effort to accelerate its global growth already advancing through VIÁGO's aggressive brand campaign and streamlined membership offer to avail Stemtech's products to a growing savvy member base in addition to leading development of regionalized versioning of benefits to maximize customer value and appeal and referral virality.
Laying the foundation for and expanding the conglomerate portfolio, the Company will focus its attention on expanding its business to address the needs and desires of everyday people wanting to experience life better, longer.
Additional information about the transaction is provided in the Company's 8-K filing with the SEC.
https://www.barchart.com/story/news/29888586/...-agreement
Stemtech Corporation (OTC-BB:STEK) is pleased to announce the merger agreement with Seacret Direct / VIÁGO, progressing their plan to establish a global leadership position in defining the future of lifestyle, health and longevity. The transaction will be completed through the issuance of 13 million preferred shares with a stated value of $2.50 per share.
Stemtech Corporation ("Company"
and Seacret have signed the agreement to complete the previously announced merger. The completion of this transaction remains subject conditions, including the audit of Seacret Direct / VIÁGO, consents and authorizations of the preferred stock and other customary conditions. This transaction marks a pivotal milestone in the Company's evolution, expected to double the Stemtech revenue, in combination. The merger creates a vertically integrated powerhouse poised to lead and redefine health, longevity, and lifestyle for a public that demands smarter, more comprehensive solutions to improving quality of daily life. Highlighting a consolidated revenue forecast of double or more for 2025 with planned cost synergies, the merger is set to deliver positive bottom-line results through optimization and existing growth trajectories alone.
The Company will focus effort to accelerate its global growth already advancing through VIÁGO's aggressive brand campaign and streamlined membership offer to avail Stemtech's products to a growing savvy member base in addition to leading development of regionalized versioning of benefits to maximize customer value and appeal and referral virality.
Laying the foundation for and expanding the conglomerate portfolio, the Company will focus its attention on expanding its business to address the needs and desires of everyday people wanting to experience life better, longer.
Additional information about the transaction is provided in the Company's 8-K filing with the SEC.
https://www.barchart.com/story/news/29888586/...-agreement
(0)
(0)